Zealand Pharma Sells Rusfertide Royalty to Royalty Pharma for $100 Million

Company: Zealand Pharma / Royalty Pharma · Event Type: Royalty Monetization · Product/Asset: Rusfertide (PTG-300) · Announcement Date: August 12, 2026 Summary Zealand Pharma sold its legacy economic interests in rusfertide, Takeda’s investigational hepcidin-mimetic therapy for polycythemia vera, to Royalty Pharma for $100 million—$50 million…